MicroPort Scientific Corporation

10/13/2021 | Press release | Archived content

MicroPort® Shared Latest Research Results at China Heart Congress (CHC) and 6th China Vascular Congress (CVC)

Beijing, China, 12 October 2021 - Recently, Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) presented a satellite session at the China Heart Conference (CHC) in conjunction with the 6th China Vascular Conference (CVC). The Conference, co-organized by the National Center for Cardiovascular Diseases, the Chinese Circulation Journal, and the Beijing Kaiqi Cardiovascular Foundation, and hosted by the Fuwai Hospital of the Chinese Academy of Medical Sciences, brought together nearly 200 experts and scholars with an interest in heart and cardiovascular health to observe and exchange insights.

The satellite session, held on the first day of the conference and themed, 'MicroPort® Innovation for Homegrown Products', was facilitated by Runlin Gao from the Fuwai Hospital of the Chinese Academy of Medical Sciences, and co-chaired by President Lianglong Chen from the Fujian Medical University Union Hospital, Prof. Zening Jin from the Beijing Tiantan Hospital Affiliated to the Capital Medical University, and Director Qi Zhang from the Shanghai East Hospital.

During the satellite session, Prof. Bo Xu from the Fuwai Hospital of Chinese Academy of Medical Sciences presented the one-year results of FUTURE-II, a randomized controlled trial for the Firesorb® Bioresorbable Rapamycin Targeted Eluting Coronary Scaffold System (Firesorb®). Prof. Bo Xu spoke highly of Firesorb®'s performance, noting that the one-year data from the FUTURE-II trial demonstrated for the first time the effectiveness of the thinner strut design of the product. He further commented on the significance of the results, highlighting that the favorable outcomes of the trial may open up opportunities for applying PLLA-based bioresorbable stents in future clinical investigation and practices.

Mr. Ming Zheng, Senior Vice President of Clinical Medicine at MicroPort®, shared the latest progress of the TARGET program, a global clinical program for the Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®). The TARGET CTO clinical research program is a prospective, multi-center, randomized controlled clinical trial for Firehawk® in handling the most complex CTO lesion with a primary endpoint of 12-month in-stent late loss. The program is anticipated to enroll approximately 1,616 patients at up to 100 hospitals across the United States, Canada, Europe, and Japan, including 50 patients in the OCT subgroup and 200 patients in the quantitative coronary angiography (QCA) subgroup (with a 13-month follow-up).

In addition, Prof. Haibo Jia, from the Second Affiliated Hospital of Harbin Medical University, presented a case he had worked on using the 3D-OCT guided Firehawk® implantation for complex bifurcation lesions. He commented that the unique design platform of the Firehawk® stent provided a larger maximal expansion diameter and lateral hole area, which facilitated the clinical operation during the two-stent placement. He added that the single-sided grooved design showed the product's unique advantage in protecting the drug coating when placing the stent.

About Shanghai MicroPort Medical (Group) Co., Ltd.

Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®), is a subsidiary of MicroPort Scientific Corporation (Group) Co., Ltd. (stock code: 00853.HK). As a leader in high-end innovative medical solutions, MicroPort® places emphasis on the human dimension while integrating the pursuit of perfection and innovation into the corporate DNA. In the future, MicroPort® will continue to promote and share cutting-edge academic information and clinical experience, contribute to the academic exchange in the field of cardiovascular disease, and provide more total solutions that will help extend and reshape patients' lives.